IL2 and cancer: Since IL-1β, TNF-α, and IFN-γ cytokines are believed to mediate cytotoxicity of IL-2 based immunotherapies4,19, mutant IL-2 with reduced binding to the high-affinity IL-2R may be more effective and less toxic for cancer treatment19,28–30.